Top

BY Kelley Murfin

Findings from three studies led by researchers at MD Anderson suggest that new combination therapies are safe and effective against various types of leukemia. The investigators believe that the promising data about the use of these therapeutic regimens may lead to new standards of care and more leukemia treatment options. Results from the clinical trials were presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting...

AML MDS Trials

BY Clayton Boldt, Ph.D.

In patients with leukemia, complete remission after treatment is currently defined by the absence of cancer cells in a bone marrow biopsy...

BY Clayton Boldt, Ph.D.

Repurposing FDA-approved therapies is a cost-effective way to bring new treatments to patients in need, but identifying those drugs with benefits...

BY Clayton Boldt, Ph.D.

Leukemia researchers at The University of Texas MD Anderson Cancer Center, working collaboratively with the Therapeutics Discovery division, have advanced a first-in-class therapeutic antibody into a Phase I clinical trial for patients with high-risk acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myeloproliferative neoplasms.

The antibody, known as h8F4, is a T-cell receptor (TCR)-like antibody that can kill...

Visualization of the PR1 peptide target on the surface of AML cells.

BY Ron Gilmore

Researchers in MD Anderson’s Leukemia department played central roles in the studies of two drugs, glasdegib and venetoclax, approved in November...

BY Clayton R. Boldt, Ph.D.

MD Anderson’s Moon Shots Program™ was established to bring teams of world-class clinicians and researchers together in order to rapidly advance...

BY Ron Gilmore

Somatic mutations in certain genes may function as a molecular minimal residual disease marker for acute myeloid leukemia (AML), according...

BY Clayton R. Boldt, Ph.D.

Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) encompass a spectrum of diseases characterized by an overproduction of immature...

BY Clayton Boldt, Ph.D.

Older patients with non-metastatic breast cancer who have been treated modern chemotherapy drugs have a greater risk of secondary acute myeloid...

BY Ron Gilmore

Researchers from MD Anderson Cancer Center presented their latest findings involving drug treatments for blood cancers at the American...